Image Courtesy: Shutterstock
Scientists at the University of California, San Francisco (UCSF) have developed an experimental immune cell therapy that completely eliminated an aggressive childhood brain cancer in mice. The treatment, called B-SYNC, cleared tumors in every treated animal across two disease models and provided lasting protection against a second exposure to cancer cells.
The therapy uses genetically engineered immune cells that activate their cancer-fighting receptors only after entering the brain. This approach could help overcome one of the biggest challenges in treating brain tumors, targeting cancer cells effectively while limiting damage to healthy tissue. The findings were published in Science Translational Medicine on October 28, 2026.
The research focuses on diffuse midline glioma (DMG), one of the most aggressive childhood brain cancers. The disease often develops in the brainstem, which controls essential functions such as breathing, swallowing, and heart rate. Because tumors infiltrate surrounding healthy tissue, surgery is generally not a viable option. Most children diagnosed with DMG survive less than a year.
CAR-T therapy, which modifies a patient’s immune cells to recognize and destroy cancer, has shown significant success against certain blood cancers. However, applying the approach to brain tumors has proved difficult because of the risk of damaging healthy tissue and the challenge of targeting cancer cells consistently.
B-SYNC addresses this problem using a molecular sensor called synNotch. The sensor detects brevican, a protein commonly found in the brain, and triggers the production of cancer-targeting receptors. Once activated, these receptors recognize two proteins, EphA2 and IL13R?2, found on many DMG cells.
This design effectively creates a biological switch, allowing the engineered immune cells to activate their cancer-fighting capabilities inside the brain rather than throughout the body.
In experiments, researchers initially administered B-SYNC cells intravenously, allowing some of them to travel into the brain and attack tumors. However, the strongest results came from injecting the engineered cells directly into the brain’s fluid-filled ventricles. This method eliminated tumors in every treated mouse across both human DMG models, while conventional CAR-T cells failed to control the cancer.
The treatment also demonstrated an unexpected ability to provide long-term protection. Nearly seven weeks after the initial tumors disappeared, researchers introduced another batch of cancer cells into the previously treated mice. Every animal rejected the new cancer cells, suggesting that the engineered immune cells remained active and capable of recognizing the disease.
Researchers believe restricting CAR activation to the brain could help prevent T cell exhaustion, a condition in which immune cells gradually lose their ability to fight cancer after prolonged stimulation. However, further experiments are needed to establish whether this mechanism explains the treatment’s effectiveness.
The UCSF team is now preparing to move B-SYNC into human clinical trials, potentially beginning in April 2027. The initial study will involve children and young adults with brain tumors and evaluate different methods of administering the engineered cells, including injections into the brain’s ventricles.
Despite the remarkable mouse results, the treatment has not yet been tested in humans. Researchers will need to establish its safety, determine appropriate dosages, and assess whether the same tumor-clearing results can be achieved in patients.
